CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
Abstract Chimeric antigen receptor (CAR) T‐cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times. As the clinical use has progressed rather rapidly since the first...
Main Authors: | Alankrita Taneja, Tania Jain |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | eJHaem |
Subjects: | |
Online Access: | https://doi.org/10.1002/jha2.350 |
Similar Items
-
Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy
by: Supavit Chesdachai, et al.
Published: (2021-01-01) -
Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
by: Yuan Xia, et al.
Published: (2022-12-01) -
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
by: Elien De Bousser, et al.
Published: (2021-12-01) -
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01) -
Chimeric Antigen Receptor beyond CAR-T Cells
by: Vicky Mengfei Qin, et al.
Published: (2021-01-01)